

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
8 March 2007 (08.03.2007)

PCT

(10) International Publication Number
WO 2007/026959 A3

(51) International Patent Classification:

C07D 409/12 (2006.01) C07D 417/12 (2006.01)
C07D 333/54 (2006.01) A61K 31/559 (2006.01)
C07D 407/12 (2006.01) A61P 25/00 (2006.01)
C07D 413/12 (2006.01)

(21) International Application Number:

PCT/JP2006/317704

(22) International Filing Date: 31 August 2006 (31.08.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2005-251055 31 August 2005 (31.08.2005) JP

(71) Applicant (for all designated States except US): OTSUKA PHARMACEUTICAL CO., LTD. [JP/JP]; 9, Kanda-Tsukasacho 2-chome, Chiyoda-ku, Tokyo, 1018535 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YAMASHITA, Hiroshi [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). KURODA, Hideaki [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). ITO, Nobuaki [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). MIYAMURA, Shin [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). OSHIMA, Kunio [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). MATSUBARA, Jun [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 224-18, Ebisuno, Hiraishi, Kawauchicho, Tokushima-shi, Tokushima, 7710182 (JP). TAKAHASHI, Haruka [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). FUKUSHIMA, Tae [JP/JP];

c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). SHIMIZU, Satoshi [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). KONDO, Kazumi [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). SAKURAI, Yohji [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). KURODA, Takeshi [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). TAIRA, Shinichi [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 224-18, Ebisuno, Hiraishi, Kawauchicho, Tokushima-shi, Tokushima, 7710182 (JP). ITOTANI, Motohiro [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). TANAKA, Tatsuyoshi [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP).


(74) Agents: ASAMURA, Kiyoshi et al.; Room 331, New Ohtemachi Bldg., 2-1, Ohtemachi 2-chome, Chiyoda-ku, Tokyo 1000004 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,

[Continued on next page]

(54) Title: DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS



(1)

(57) Abstract: A heterocyclic compound or a salt thereof represented by the formula (1): where R^2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R^1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.



RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:
16 August 2007

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.